ABSTRACT
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a gender or age predilection. The diagnosis of EDP is essentially clinical, with histopathology findings being nonspecific. To date, treatment for EDP varies. The use of several therapies, including dapsone, clofazimine, retinoid A, tacrolimus, and ultraviolet light have been reported but with minimal effectiveness.5 We report a case of EDP occurring in a patient following the COVID-19 vaccine that was given topical ruxolitinib with success in treatment. To our knowledge, this is the first report of the use of topical ruxolitinib in treatment of EDP with successful management. J Drugs Dermatol. 2022;22(3): doi:10.36849/JDD.7156.
Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , Erythema/chemically induced , Erythema/diagnosis , Erythema/drug therapyABSTRACT
severe distinctive cutaneous drug reaction, generalized pustular figurate erythema, closely linked with hydroxychloroquine (HCQ), has been documented. It is distinguishable from AGEP by its longer incubation, more varied morphology (initially urticarial and later targetoid, arcuate plaques), recalcitrance to therapy and longer disease course. Aim of the article is to review the recognized entity associated with ingestion of hydroxychloroquine in patients infected with COVID-19. A systematic review using electronic search was performed. Inclusion criteria: n patients with COVID-19 demonstrated by PCR, with typical clinical features of AGEP/GPFE or atypical features associated with typical histopathology. We used the (JBI) Critical Appraisal Checklist for Case Reports for the qualitive assessment. We included 13 publications. Their overall quality was good to moderate. Only 27.3% of the patients had a severe COVID-19 course. The mean lag time between trigger exposure and rash development was 24 days. Only 15.38% of the reported AGEP were clinically typical, while the remaining 69.23 % were suggestive of GPFE. Unfortunately, 2 patients died secondary to massive pulmonary embolism. In COVID-19 infection, we suggest reconsidering treating established COVID-19 empirically with HCQ, as both triggers can augment the subsequent cytokine storm, inducing a severe drug reaction and possibly increasing the risk of thrombo-embolic events.
Subject(s)
Acute Generalized Exanthematous Pustulosis , COVID-19 , Humans , Hydroxychloroquine/adverse effects , Acute Generalized Exanthematous Pustulosis/drug therapy , Acute Generalized Exanthematous Pustulosis/etiology , COVID-19 Drug Treatment , Erythema/drug therapySubject(s)
Edema , Erythema , Child , Edema/diagnosis , Edema/etiology , Erythema/diagnosis , Erythema/drug therapy , Erythema/etiology , Humans , SyndromeABSTRACT
BACKGROUND: The coronavirus disease 2019 (COVID-19) is associated with a wide clinical spectrum of skin manifestations, including urticarial, vesicular, vasculitic and chilblain-like lesions. Recently, delayed skin reactions have been reported in 1% individuals following mRNA vaccination against SARS-CoV-2. The exact pathophysiology and the risk factors still remain unclear. PATIENTS AND METHODS: 6821 employees and patients were vaccinated at our institutions between February and June 2021. Every patient received two doses of the mRNA-1273 vaccine in our hospitals, and reported back in case of any side effects which were collected in our hospital managed database. RESULTS: Eleven of 6821 vaccinated patients (0.16%) developed delayed skin reactions after either the first or second dose of the mRNA-1273 vaccine against SARS-CoV-2. Eight of 11 patients (73%) developed a rash after the first dose, while in 3/11 (27%), the rash occurred after the second dose. More females (9/11) were affected. Four of 11 patients required antihistamines, with two needing additional topical steroids. All the cutaneous manifestations resolved within 14 days. None of the skin reactions after the first dose of the vaccine prevented the administration of the second dose. There were no long-term cutaneous sequelae in any of the affected individuals. CONCLUSION: Our data suggests that skin reactions after the use of mRNA-1273 vaccine against SARS-CoV-2 are possible, but rare. Further studies need to be done to understand the pathophysiology of these lesions.
Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Dermatitis/etiology , Erythema/etiology , 2019-nCoV Vaccine mRNA-1273 , Adult , Aged , Dermatitis/drug therapy , Dermatitis/epidemiology , Erythema/drug therapy , Erythema/epidemiology , Female , Histamine Antagonists/therapeutic use , Humans , Male , Middle Aged , Steroids/therapeutic use , Vaccination/adverse effectsSubject(s)
COVID-19/pathology , Exanthema/pathology , COVID-19/diagnosis , COVID-19 Nucleic Acid Testing , Dexamethasone/therapeutic use , Erythema/drug therapy , Erythema/pathology , Exanthema/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Middle Aged , Radiography, Thoracic , SARS-CoV-2Subject(s)
Ageusia/drug therapy , Anosmia/drug therapy , COVID-19/complications , Doxycycline/therapeutic use , Erythema/drug therapy , Skin Diseases, Genetic/drug therapy , Adult , Ageusia/diagnosis , Ageusia/immunology , Anosmia/diagnosis , Anosmia/immunology , Biopsy , COVID-19/diagnosis , COVID-19/immunology , COVID-19/virology , COVID-19 Serological Testing , Drug Repositioning , Erythema/diagnosis , Erythema/immunology , Erythema/pathology , Female , Humans , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Skin/immunology , Skin/pathology , Skin Diseases, Genetic/diagnosis , Skin Diseases, Genetic/immunology , Skin Diseases, Genetic/pathology , Treatment OutcomeABSTRACT
SARS-CoV-2 (COVID-19) is highly-contagious. It can lead to respiratory distress-and in some cases-death. Recent reports and observations have identified an association between COVID-19 and manifestations in the feet. However, there are very few reports that describe the course of these foot manifestations in any detail. The authors present a case study chronicling the progression of foot issues in a COVID-19 positive patient who also was positive for the Epstein-Barr virus.